Pivotal readout

Innovent Gastric Cancer Data

At ESMO 2026, phase 3 G-HOPE-001 data showed median overall survival of 10.2 months with IBI343 versus 6.9 months with physician's choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. In a phase 1b study, first-line IBI363 plus XELOX achieved an 80% confirmed response rate and 12.4-month median progression-free survival in HER2-negative advanced disease. The expert describes precision targeting and combination treatment as promising directions, while noting that IBI363 remains at the proof-of-concept stage and needs phase 3 confirmation.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call